Novartis Gene Therapies Global Managed Access Program
Novartis Gene Therapies recommits to Global Managed Access Program for 2021 so that children around the world can benefit from SMA treatment who otherwise would not have access to Zolgensma.
Novartis announced the company’s financial results for the second quarter and first half of 2022.
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
In 2021, we continued to reimagine medicine and deliver on our purpose to improve and extend people’s lives. See more in our Integrated Report.
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices.
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.
Novartis Gene Therapies recommits to Global Managed Access Program for 2021 so that children around the world can benefit from SMA treatment who otherwise would not have access to Zolgensma.